Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions.

Abstract: A pharmaceutical composition comprising a non-toxic effective amount of an actinide decorporation agent and a pharmaceutically acceptable carrier therefore, the actinide decorporation agent comprising a hexacoordinate desferrithiocin analogue capable of chelating an actinide in vivo and a method for removing an actinide from the tissue of a human or nonhuman mammal.

Abstract: The invention relates to compositions and methods of treatment using an iron chelator, an antioxidant, estrogen, and/or combinations thereof, optionally, linked to a nanoparticle, to treat a subject in need thereof. The compositions and methods may be used to restore or protect the normal functions of osteoblast and osteoclast by depleting iron and inhibiting oxidative damage. The compositions and methods may also be used to increase the bone formation rate in a subject.

Abstract: The present invention provides a liquid seasoning, which brings on a sufficient salty taste although it has a low sodium concentration, and which exhibits for example a pharmacological effect such as an antihypertensive effect at a high level. The present invention relates to a liquid seasoning, which contains the following components (A) to (D): (A) 3.55% or less by weight of sodium; (B) 0.5% to 4.2% by weight of potassium; (C) more than 2% by weight of an acidic amino acid and/or more than 1% by weight of a basic amino acid; and (D) 0.05% to 10% by weight of a food material having an antihypertensive effect.

Abstract: This invention relates to methods for treating cardiovascular disorders selected from heart failure, thromboembolic disorders, venous diseases, and fibriotic disorders other than fibrosis of the liver, comprising administering an effective amount of a compound of formula (I) wherein the several variables are as defined in the specification and claims.

Abstract: An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer. Most preferably, the metal chelator is EDTA or a salt of EDTA, and the transport enhancer is methylsulfonylmethane (MSM). The formulation may be in a form suitable for application to the eye itself, for example, in the form of eye drops.

Abstract: Methods and formulations are provided for the treatment of localized edema, particularly localized edema resulting from chronic venous insufficiency. A metal ion sequestrant is topically administered to a subject afflicted with localized edema in combination with a permeation enhancer selected from methylsulfonylmethane and a combination of methylsulfonylmethane and dimethylsulfoxide. Topically administrable formulations for use in the aforementioned method are also provided.

Abstract: The present invention provides a liquid seasoning, which brings on a sufficient salty taste although it has a low common salt concentration, and which exhibits for example a pharmacological effect such as an antihypertensive effect at a high level. The present invention relates to a liquid seasoning, which contains the following components (A) to (C): (A) 3.55% or less by weight of sodium; (B) 0.5% to 4.2% by weight of potassium; and (C) 0.1% to 10% by weight of a food material having an antihypertensive effect, wherein the remaining portion of the liquid seasoning excluding component (C) is adapted by incorporation of a substance other than component (C) to have a nitrogen content (D) of 1.6% or more based on the total weight of the liquid seasoning.

Abstract: Methods and compositions are provided for the treatment of inflammation and disorders, diseases, and adverse conditions, i.e., pathologies, caused by or otherwise associated with inflammatory processes. A metal ion sequestering agent that directly or indirectly exerts an anti-inflammatory effect is administered to a subject in combination with a sequestration inactivating moiety that facilitates transport of the metal ion sequestering agent through biological membranes. The sequestration inactivating moiety also inactivates the metal ion sequestering agent until association between the two components is cleaved in vivo to release the active sequestering agent. Compositions containing a metal ion sequestering agent and a sequestration inactivating moiety are also provided; the compositions optionally contain an added anti-inflammatory agent.

Abstract: A present invention relate to a diethylenetriaminepentaacetic acid (DTPA)-modified ferrofluid and a preparation method of the same. The DTPA-ferrofluid contains DTPA and a nano ferrofluid. The DTPA-ferrofluid can be further mixed with a peptide. Unmodified or modified peptide ferrofluids prepared from the DTPA-modified ferrofluid, such as unmodified or modified octreotide-containing or unmodified or modified lanreotide-containing ferrofluid.

Abstract: A composition may include a combination of at least one chelating agent and at least one antioxidant agent, the combination may have a fractional inhibitory concentration coefficient of about 0.5 or less and/or an INR of > about 2.82.

Abstract: The present invention relates to stable parenteral formulations of tigecycline and process of preparation thereof, wherein the formulation comprises of an edetate, a pH modifying agent or an antioxidant, such that the formulation remains stable for at least 45 hours.

Abstract: Disinfectant compositions comprising PHMB and EDTA salt(s) are disclosed. The disinfectant compositions have also demonstrated activity as enhanced, fast acting catheter lock/flush solutions. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.

Abstract: A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.

Abstract: The invention is directed to an ophthalmic composition comprising a disuccinate of formula I or a corresponding salt thereof; wherein R1 is selected from hydrogen, alkyl or —C(O)alkyl, the alkyl having one to twelve carbons and optionally one or more oxygen atoms, A is a methylene group or an oxyalkylene group, and n is from 2 to 8. The ophthalmic composition also includes a cationic antimicrobial component and a tonicity agent, wherein the tonicity agent provides for an osmolality of the composition from 200 mOs/kg to 420 mOsm/kg.

Abstract: This invention relates to the use of chemical compounds showing non-competitive and selective GluR5 antagonist or partial agonist activity for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

Abstract: The present invention provides methods for ameliorating, overcoming, or inhibiting insulin resistance in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of LR-90 and LR-102, or a pharmaceutically acceptable salt or derivative thereof. Methods of treating type 2 diabetes and diabetic nephropathy, or preventing or slowing their development are also encompassed by the invention.

Abstract: The invention relates to clear, liquid preservatives, which contain a) one or several 1-hydroxy-4-methyl-6-alkyl-2(1H)-pyridones and/or one or several salts thereof. wherein alkyl represents a linear, branched or cyclic alkyl group having 1-12 carbon atoms, and b) one or several alcohols containing one or several aromatic groups.

Abstract: This invention provides a method of treating solid tumors which comprises administering an effective amount of a combination of (1) a bioresponse modifier and (2) a chemotherapeutic agent. This invention also provides a method of potentiating the effects of a chemotherapeutic regimen in a mammal in need of treatment with such regimen which comprises administering a bioresponse modifier in addition to a chemotherapeutic regimen.

Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds.

Abstract: Particular nutritional supplements and protocols emphasize the use of ethylenediamine tetraacetic acid as a mouth rinse, and as an enteric-coated oral pharmaceutical, further supplemented on a daily basis with both a combination of phosphatidyl lipids and alpha lipoic acid and a nutritional supplement containing approximately equal amounts of Reishi and Shiitake mushrooms.

Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.

Abstract: The present invention relates to a diclofenac sodium oral pharmaceutical containing diclofenac sodium, a nonionic surfactant, a cholic acid derivative as an absorption promoting agent, and a glycerin or a glycol. The oral pharmaceutical has a rapid-acting effect and a good internal absorption even under non-fasting condition. Further, the pharmaceutical can be processed in a hard capsule pharmaceutical by filling it in a hard capsule as such, and has an excellent internal absorption under non-fasting condition, similarly to suppositories.

Abstract: Composition, non-aerosol dispenser containing the composition, and method of raising the blood glucose level of an individual comprising administering an effective amount of the composition to an oral mucosa of the individual. The composition comprises: a. an effective amount of glucose, b. an effective amount of at least one absorption enhancer chosen from lecithin, hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening primrose oil, menthol, trihydroxy oxo cholanyl glycine, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers, polidocanol alkyl ethers, chenodeoxycholate, deoxycholate, alkali metal salicylate, pharmaceutically acceptable edetate, and pharmaceutically acceptable salts and analogues thereof, and c. an effective amount of a pharmaceutically acceptable carrier, wherein the composition is free of any active pharmaceutical agents.

Abstract: A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is decreased so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day. Experiments have been performed to demonstrate the importance of the addition of specific acids to hexameric insulin to enhance speed and amount of absorption and preserve bioactivity following dissociation into the monomeric form by addition of a chelator such as EDTA.

Abstract: The invention relates to a method for impregnating, incorporating or surface-treating substances/articles that can be microbially decomposed, contaminated and/or infested with parasites and/or that are perishable. The inventive method comprises the following steps: applying a special antimicrobial/antiparasite composition on the substances/articles or incorporating the antimicrobial/antiparasite composition in the substances. The invention further relates to said special antimicrobial/antiparasite compositions, to their use for impregnating and/or surface-treating substances that can be microbially decomposed, contaminated and/or that are perishable or substances that are infested with parasites and to the use thereof in substances and products that have to be self-contaminating.

Abstract: An ophthalmic pharmaceutical composition containing acetylcysteine as the active ingredient having a mucolitic action, suitable for administration in eyedrops, where N-acetyl-cysteine is neutralised with base DEAE-dextrane in order to reach pH levels preferably between 6.0 and 7.5, and having a physiologically acceptable osmolarity less than 320 mOsm/kg. The presence of a neutralising agent for N-acetyl-cysteine that does not negatively affect the composition osmolarity allows the formulation to be isotonic or even hypotonic, thus avoiding the irritative and potentially damaging effects of previous ophthalmic products containing N-acetyl-cysteine.

Abstract: A composition which causes adult boring bark beetles to discontinue boring, discontinue laying eggs and become disoriented and bore out of the tree or cease boring altogether and die is described. Additional tests have shown that beetles will not infest a tree which has been treated with the composition. Furthermore, the composition also causes beetle larvae to cease boring and die and also causes egg sacks to shrivel and die.

Abstract: A method for treating a joint pain in a subject comprising providing an effective amount of an anti-angiogenic agent to a synovial capsule adjacent to the joint.

Abstract: The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are refractory to treatment with recombinant human erythropoietin (EPO) are encompassed herein.

Abstract: Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanine, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histidine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia.

Abstract: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.

Abstract: Disclosed are pharmaceutical compositions comprising a thrombin peptide derivatives and a chelating agent and/or a pharmaceutically acceptable thiol-containing compound. The pharmaceutical compositions optionally further comprise an antioxidant. Also, disclosed are methods for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment. The methods comprise the step of administering an effective amount of a thrombin peptide derivative in the pharmaceutical composition described above.

Abstract: The present invention relates to methods of treating an allergic or non-allergic respiratory disorder by administering orally a composition of lactoferrin alone or in combination with metal chelators to treat respiratory disorders.

Abstract: This invention relates to the methods and pharmaceutical compositions for treating diseases or disorders associated with oxidative stress and/or genomic instability. In particular, the invention relates to methods for treating ataxia-telangeictasia (AT) and such disease states by administering a therapeutically effective amount of a chelating agent to increase genomic stability and/or decrease oxidative stress.

Abstract: A composition of biochemical compounds involved in bioenergy metabolism of cells and a method of use in prevention and therapy of diseases are disclosed.

Abstract: The present invention is directed to a composition for treating burns. The composition comprises a therapeutically effective amount of one or more weak organic acid compatible with human skin, in a pharmacologically effective carrier delivered at a pH of about 2.5–4.5. The weak organic acid is preferably selected from the group consisting of acetic acid, vinegar, citric acid and combinations thereof and the pharmacologically effective carrier is preferably an aqueous based carrier, more preferably a gel form, utilizing a CARBOPOL as a gelling agent. The composition may also include one or more other agents selected from sun blocking agents, skin moisturizing agents, herb extracts and antimicrobial agents.

Abstract: The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of hydrogen, C1-C8 alkyl substituted C1-C8 alkyl, aryl-C0-4-alkyl, substituted aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, substituted heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and substituted C3-C6 cycloalkylaryl-C0-2-alkyl; (b) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; (c) Y is C, O, S, NH or a single bond; and (d) E is selected from the group consisting of hydrogen, C(R3)(R4)A, A, (CH2)n COOR19 and substituted (CH2)n COOR19.

Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.

Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing the same as well as a method for treatment of parasitic disorders, wherein said compounds are administered. The present compounds are especially well suited for treatment of coccidiosis, particularly in poultry, and they have general formula (I): where Y is S or O and R is as defined in the specification.

Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.

Abstract: An anti-microbial composition comprising:

Abstract: A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment.

Abstract: A novel class of dicarboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: The invention treats proteinase-related disorders by interfering with the binding of the metal needed by matrix metalloproteinases, such as PLA-2. The compounds used are known microbial-based chelators of known high solubility. For example, dipicolinic acid has a high affinity to calcium and is soluble in both water and glycerin, as might be expected due to its role in the formation of bacterial endospores. Thus, unlike most chelation agents, the compounds are intended to be permeable enough to cross a vertebrate's cell membrane, a prerequisite for meaningful inhibition of protein-regulated cellular functions such as the inflammatory cascade and accompanying formation of free fatty acids.

Abstract: L-threo-&bgr;-benzyloxyaspartate derivatives having a substituent on the benzene ring, represented by the following formula (1): 1

Abstract: A water treatment agent and method of treating water to inhibit, reduce, or prevent the formation of algae and bacteria in a water body. The water treatment agent may include copper sulfate penta-hydrate and/or silver, di-sodium ethylene di-amine tetra-acetic acid dihydrate, a scale inhibitor, a shocking agent and a buffer agent. For instance, the treatment agent may include a composition of copper sulfate pentahydrate, di-sodium ethylene di-amine tetra-acetic acid, monopotassium phosphate or sulfuric acid, and potassium monopersulfate and 1-hydroxyethylidene-1,1-diphosphonic acid.

Abstract: The present invention forms a mixture basically consisting of threonine, proline, glycine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, aspartic acid, serine, glutamic acid, alanine, methionine, histidine and arginine as a unit, by which a body temperature raising effect was observed. The similar body temperature raising effect was observed when carnitine and/or tryptophan is added to the unit. These groups were found to be amino acid mixture-containing agents capable of raising body temperature for food or drink use or medical use. The agents have excellent body temperature raising effect, thereby having the functions of reduction of accumulated body fat, alleviation of excess sensitivity to cold, warming of a cold body, and the like.

Abstract: The present invention relates to the use of N-arylmethylene ethylenediaminetriacetates, N-arylmethylene iminodiacetates or N,N′-diarylmethylene ethylenediamineacetates, their salts or metal complexes to increase the production of nitric oxide in or on the skin or scalp or the mucous membranes as well as a procedure for the application of nitric oxide in or on the skin, the scalp or the mucous membranes. It also relates to a cosmetic treatment procedure which makes use of these compounds as donors of NO.